Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash from Financing Activities (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Cash from Financing Activities for 16 consecutive years, with $14.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 1178.85% year-over-year to $14.0 million, compared with a TTM value of $610000.0 through Dec 2025, down 88.09%, and an annual FY2025 reading of $610000.0, down 88.09% over the prior year.
  • Cash from Financing Activities was $14.0 million for Q4 2025 at Amicus Therapeutics, up from -$1.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $201.1 million in Q3 2021 and bottomed at -$13.3 million in Q1 2024.
  • Average Cash from Financing Activities over 5 years is $13.6 million, with a median of $625000.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities tumbled 192.35% in 2022, then soared 6829.7% in 2023.
  • Year by year, Cash from Financing Activities stood at -$104000.0 in 2021, then soared by 635.58% to $557000.0 in 2022, then soared by 1373.97% to $8.2 million in 2023, then plummeted by 86.64% to $1.1 million in 2024, then skyrocketed by 1178.85% to $14.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for FOLD at $14.0 million in Q4 2025, -$1.3 million in Q3 2025, and -$400000.0 in Q2 2025.